Novel antiviral compounds fight wide range of viruses
The data, taken from pre-clinical animal and in vitro studies, shows that the drugs prevent viral pathogens from infecting the host because the new drug’s molecules provoke an antiviral immunity that is innate to the body and not triggered by a specific viral target alone.
The drug compounds have been tested against Ebola, dengue and influenza viruses in mouse subjects.
“These small molecule compounds trigger a natural immune response by targeting processes that activate the innate immune transcription factor, IRF-3, a critical responder that drives antiviral gene expression to suppress viral replication,” Kineta Chief Scientific Officer Shawn Iadonato said. “Current direct-acting antivirals that typically have selective action against a single virus have a high risk of eliciting drug resistance. These novel and potent host-directed innate immune molecules offer broad spectrum protection without development of drug resistance, and we believe our approach to developing a therapy for Ebola is the first of its kind.”
Further details were presented by company representatives at the seventh International Symposium on Filoviruses.